miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer

Thumbnail Image

Files

miR-7, miR-10a and miR-143_2026.pdf (957.35 KB)
Identifiers
URI: https://hdl.handle.net/11268/16780
DOI: 10.2147/PGPM.S313594

Publication date

2021

Authors

Gilsanz Muñoz, María Fuencisla
Galán Burgos, Miguel

Advisors

Editors

Journal Title

Journal ISSN

Volume Title

Publisher

SDG

goal-3

Metrics

Google Scholar

Research Projects

Organizational Units

Journal Issue

Abstract

Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor A. It is currently used in combination with chemotherapy to treat metastatic colorectal cancer. This therapy is not equally effective in every patient; in some, mechanisms of resistance arise that remain poorly understood. The aim of the present work was to determine whether the expression of 26 miRNAs could be associated with the effectiveness of bevacizumab plus chemotherapy, with progression-free survival (PFS), and with overall survival (OS) in metastatic colorectal cancer.

Description

UNESCO Subjects

Cáncer
Investigación médica
Tecnología médica

Keywords

Bibliographic reference

Romero-Lorca, A., Novillo, A., Gaibar, M., Gilsanz, M. F., Galán, M., Beltrán, L., Antón, B., Malón, D., Moreno, A., & Fernández-Santander, A. (2021). Mir-7, mir-10a and mir-143 expression may predict response to bevacizumab plus chemotherapy in patients with metastatic colorectal cancer. Pharmacogenomics and Personalized Medicine, Volume 14, 1263-1273. https://doi.org/10.2147/PGPM.S313594
Editor's version
https://doi.org/10.2147/PGPM.S313594

Type of document

journal article

Collections

Área de Biotecnología y Biología Molecular
Attribution-NonCommercial 4.0 International

La licencia de este ítem se describe como Attribution-NonCommercial 4.0 International